Conformationally constrained butyrophenones with mixed dopaminergic (D2) and serotoninergic (5-HT2(A), 5-HT2(C)) affinities: Synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and - thienocycloalkanones as putative atypical antipsychotics

Journal of Medicinal Chemistry

Volumn 42, Issue 15, 1999, Pages 2774-2797

  Raviña, Enrique ^a   Negreira, Jesús ^a   Cid, José ^a   Masaguer, Christian F ^a   Rosa, Elizabeth ^a   Rivas, M Emilia ^a   Fontenla, José A ^a   Loza, M Isabel ^a   Tristán, Helena ^a   Cadavid, M Isabel ^a   Sanz, Ferran ^b   Lozoya, Estrella ^b   Carotti, Angelo ^c   Carrieri, Antonio ^c  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; BUTYROPHENONE DERIVATIVE; CYCLOALKANONE; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; SEROTONIN RECEPTOR;

ARTICLE; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ELECTRICITY; EXTRAPYRAMIDAL SYMPTOM; LIPOPHILICITY; MOLECULAR MODEL; PHARMACOLOGY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SCHIZOPHRENIA; STEREOCHEMISTRY;

ANIMALS; ANTIPSYCHOTIC AGENTS; AORTA, THORACIC; BRAIN; CATALEPSY; CATTLE; DOPAMINE AGENTS; ISOXAZOLES; MALE; MICE; MODELS, MOLECULAR; MOTOR ACTIVITY; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SEROTONIN AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 0033614954     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981094e     Document Type: Article

References (102)

1. For reviews, see: (a) Howard, H. R.; Seeger, T. F. Novel Antipsychotics. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: New York, 1993; Vol. 28, p 39.
2. (b) Schaus, J. M.; Bymaster, F. P. Dopaminergic Approachesto Antipsychotic Agents. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: New York, 1998; Vol. 33, p 1.
3. Seeman, P. Dopamine receptors and dopamine hypothesis of schizophrenia. Synapse 1987, 192, 481-483.
4. Sitsen, A. Current trends in antipsychotic agents. Script Report; PJB Publications: Richmond, U.K., 1990; p 57.
5. Seeman, P.; Chou-Wong, M.; Tadesco, J.; Wong, K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261, 717-719.
6. Kennedy, J. L.; Billett, E. A.; Macciardi, F. M.; Verga, M.; Parsons, T. J.; Meltzer, H. Y.; Lieberman, J.; Buchanan, J. A. Association study of dopamine D3 receptor gene and schizophrenia. Am. J. Med. Genet. 1995, 60, 558-562.
7. Bristow, L. J.; Kramer, M. S.; Kulagowski, J.; Patel, S.; Ragan, C. I.; Seabrook, G. R. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol. Sci. 1997, 18, 186-187.
8. Filton, A.; Heel, R. C. Clozapine. A review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990, 40, 722-747.
9. Schwarz, J. T.; Brotman, A. W. A clinical guide to antipsychotic drugs. Drugs 1992, 44, 981-992.
10. Rosenheck, R.; Cramer, J.; Xu, W.; Henderson, W.; Frismann, L. A comparison of clozapine and haloperidol in hospitalized patients. N. Engl. J. Med. 1997, 337, 809-815.
11. 2/D2 Antagonists: a new type of antipsychotic agent. In Progress in Medicinal Chemistry; Ellis, G. P., Luscombe, D. K., Eds.; Elsevier Sci.: Amsterdam, 1996; Vol. 33, p 186.
12. (b) Beasley, C. M.; Tollefson, G.; Tran, P.; Satterlee, W.; Sanger, T.; Hamilton, S. Olanzapine versus placebo and haloperidol: Acute phase results of the North American Double-Blind Olanzapine Trial. Neuropsychopharmacology 1996, 14, 111-123.
13. (c) Conley, R. R.; Buchanan, R. W. Evaluation of treatment-resistant schizophrenia. Schizophrenia Bull. 1997, 23, 663-674.
14. Sanders-Bush, E.; Mayer, S. E. 5-Hydroxytryptamine (Serotonin) Receptor Agonists and Antagonists. In The Pharmacological Basis of Therapeutics, 9th ed.; Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R. W., Goodman, A., Eds.; McGraw-Hill: New York, 1996; pp 249-263.
15. Meltzer, H. Y.; Matsubara, S.; Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 1989, 251, 238-246.
16. Roth, B. L.; Meltzer, H. Y. The role of Serotonin in Schizophenia. In Psychopharmacology: The Fourth Generation of Progress; Bloom, F. E., Kupfer, D. J., Eds.; Raven Press: New York, 1995; pp 1215-1227.
17. Meltzer, H. Y.; Matsubara, S.; Lee, J. C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. 1989, 25, 390-392.
18. 4 receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 1995, 120, 365-368.
19. Kapur, S.; Remington, G. Serotonin-Dopamine Interaction and Its Relevance to Schizophrenia. Am. J. Psychiatry 1996, 153, 466-476.
20. 2 Ratio Hypothesis. Curr. Med. Chem. 1994, 1, 50.
21. Gleason, S. D.; Shannon, H. E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berlin) 1997, 129, 79-84.
22. 2A receptors in the ventral pallidum. Brain Res. 1997, 761, 97-104.
23. Okuyama, S.; Chaki, S.; Kawashima, N.; Suzuki, Y.; Ogawa, S.; Kumagai, T.; Nakazato, A.; Nagamine, M.; Yamaguchi, K.; Tomisawa, K. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats. Br. J. Pharmacol. 1997, 121, 515-25.
24. Green, M. F.; Marshall, B. D., Jr.; Wirshing, W. C.; Ames, D.; Marder, S. R.; McGurk, S.; Kern, R. S.; Mintz, J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am. J. Psychiatry 1997, 154, 799-804.
25. Martin, P.; Waters, N.; Carlsson, A.; Carlsson, M. L. The apparent antipsychotic action of the 5-HT2A receptor antagonist MDL 100907 in a mouse model of schizophrenia is counteracted by ritanserin. J. Neural. Transm. 1997, 104, 561-564.
26. Padich, R. A.; McCloskey T. C.; Kehne, J. H. 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100, 907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology 1996, 124, 107-116.
27. 2A receptor antagonist for the treatment of schizophrenia. IBS's International Conference on Serotonin Receptors. Central Nervous System. Targets for New Therapeutic Agents, Philadelphia, PA, 1996.
28. Meltzer, H. Y. Atypical antipsychotic drugs: which receptors are relevant? IBS's International Conference on Serotonin Receptors. Central Nervous System. Targets for New Therapeutic Agents, Philadelphia, PA, 1996.
29. Meltzer, H. Y. Multiple serotonin/dopamine receptor interactions contribute to atypical antipsychotic drug action. Eur. Neuropsychopharmacol. 1996, 6, S-32-2.
30. Roth, B. L.; Craigo, S. C.; Choudhary, S.; Uluer, A.; Monsma, F. J., Jr.; Shen, Y.; Meltzer, H. Y.; Sibley, D. R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 1994, 268, 1403-1410.
31. Monsma, F. J.; Shen, Y.; Ward, R. P.; Hamblin, M. W.; Sibley, D. R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 1992, 43, 320-327.
32. Ward, R. P.; Hamblin, M. W.; Lachowicz, J. E.; Hoffman, B. J.; Sibley, D. R.; Dorsa, D. M. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience 1995, 1105-1111.
33. (a) Hoyer, D.; Martin, G. R. Classification and nomenclature of 5-HT receptors: a comment on current issues. Behav. Brain Res. 1996, 73, 263-268.
34. (b) Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Hartig, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. P. A. VII International Union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 1994, 46, 157-203.
35. Erdmann, J.; Nothen, M. M.; Shimron-Abarbanell, D.; Rietschel, M.; Albus, M.; Borrmann, M.; Maier, W.; Frankzek, E.; Korner, J.; Weigelt, B.; Fimmers, R.; Propping, P. The human serotonin 7 (5-HT7) receptor gene: genomic organization and systematic mutation screening in schizophrenia and bipolar affective disorder. Mol. Psychiatry 1996, 1, 392-397.
36. Largent, B. L.; Wikstrom, H.; Snowman, A. M.; Snyder, S. H. Novel antipsychotic drugs share high affinity for sigma receptors. Eur. J. Pharmacol. 1988, 155, 345-347.
37. 2 antagonistic properties. J. Pharmacol. Exp. Ther. 1988, 244, 685-693.
38. Megens, A. A. H. P.; Niemegeers, C. J. E.; Awouters, F. H. L. Behavioral disinhibition and depression in amphetaminized rats: A comparison of risperidone, ocaperidone and haloperidol. J. Pharmacol. Exp. Ther. 1992, 260, 160-167.
39. Hyttel, J.; Arnt, J.; Costall, B.; Domeney, A.; Dragsted, N.; Lembol, H. L.; Meier, E.; Naylor, R. J.; Nowak, G.; Sanchez, C.; Starsfeldt, T. Pharmacological profile of the atypical neuroleptic Sertindol. Clin. Neuropharmacol. 1992, 15 (Suppl. 1 Pt A), 267A-268A.
40. Lieberman, J. A.; Hohn, C. A.; Mikane, J.; Rai, K.; Pisciotta, A. V.; Salz, B. L.; Howard, A. Clozapine-induced agranulocytosis: non cross-reactivity with other antipsychotic drugs. J. Clin. Psychiatry 1988, 49, 271-277.
41. Cortizo, L.; Santana, L.; Raviña, E.; Orallo, F.; Fontenla, J. A.; Castro, E.; Calleja, J. M.; de Ceballos, M. L. Synthesis and antidopaminergic activity of some 3-(aminomethyl)tetralones as analogues of butyrophenone. J. Med. Chem. 1991, 34, 2242-2247.
42. 2 antagonist activity of 3-aminomethyl tetralones. Bioorg. Med. Chem. Lett. 1991, 1, 717-720.
43. Duncan, R. L., Jr.; Helsey, G. C.; Welstead, W. J., Jr.; Da Vanzo, J. P.; Funderburk, W. H.; Lunsford, C. D. Aroylpiperidines and pyrrolidines. A new class of potent central nervous system depressants. J. Med. Chem. 1970, 13, 1-6.
44. 2 serotonin receptor binding. J. Med. Chem. 1995, 38, 1196-1202.
45. Loza, I.; Ferreiro, T. G.; Sanz, F.; Lozoya, E.; Rodriguez, J.; Manaut, F.; Verde, I.; Castro, E.; Fontenla, J. A.; Cadavid, I.; Honrubia, M.; Fueyo, J.; Raviña, E. Antiserotoninergic activity of 2-aminoethyl benzocyclanones in rat aorta: Structure-activity relationships. J. Pharm. Sci. 1993, 82, 513-517.
46. Fontenla, J. A.; Osuna, J.; Rosa, E.; Castro, E.; Ferreiro, T. G.; Loza García, I.; Calleja, J. M.; Sanz, F.; Rodriguez, J.; Raviña, E.; Fueyo, J.; Masaguer, C. F.; Vidal, A.; de Ceballos, M. L. Synthesis and atypical antipsychotic profile of some 2-(2-piperidinoethyl) benzocycloalkanones as analogues of butyrophenone. J. Med. Chem. 1994, 37, 2564-2573.
47. 2A) receptors of 1-(benzoylpropyl)-4-(1-oxocycloalkyl-2-ethyl)piperazines as cyclic butyrophenone derivatives. Chem. Pharm. Bull. 1996, 44, 534-541.
48. 2A receptors. Bioorg. Med. Chem. Lett. 1995, 5, 579-584.
49. Masaguer, C. F.; Raviña, E. A practical and efficient route for synthesis of 6-aminomethyl-4-oxo-4,5,6,7-tetrahydroindoles as new CNS precursors. Tetrahedron Lett. 1996, 37, 5171-5174.
50. 2A) affinities. Synthesis of 5-aminoethyl-and 6-aminomethyl-4-oxotetrahydroindoles as potential atypical antipsychotics. Chem. Pharm. Bull. 1999, 47.
51. 2A receptors. Bioorg. Med. Chem. Lett. 1998, 8, 3571-3576.
52. For benzisoxazole-benzoyl bioisosterism see: (a) Shutske, G. M.; Setescak, L. L.; Allen, R. C.; Davis, L.; Effland, R. C.; Ranbom, K.; Kitzen, J. M.; Wilker, J. C.; Novick, W. J., Jr. [(3-Aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A New Diuretic Series. J. Med. Chem. 1982, 25, 36-44.
53. (b) Strupczewski, J. T.; Allen, R. C.; Gardner, B. A.; Schmid, B. L.; Stache, U.; Glamkowski, E. J.; Jones, M. C.; Ellis, D. B.; Huger, F. P.; Dunn, R. W. Synthesis and neuroleptic activity of 3-(1-substituted-4-piperidinyl)-1,2-benzisoxazoles. J. Med. Chem. 1985, 28, 761-769.
54. 2 receptors. J. Med. Chem. 1993, 36, 1488-1495.
55. Palermo, M. G.; Corbett, R.; Hartman, H. B.; Hrib, N. J.; Kafka, S.; Kongsamut, S.; Nmeoto, P. A.; Schilp, D. E.; Tseng, H.; Woods-Kettelberger, A.; Martin, L. L. Synthesis and evaluation of 3-(4-piperazmyl)-6-hydroxy-benzisoxazoles and depot analogues as potential atypical neuroleptic compounds. Abstracts of Papers; 214th National Meeting of the American Chemical Society, Division of Medicinal Chemistry, Las Vegas, NV, 1997.
56. Hashimoto, I.; Takatsuka, R. Friedel-Crafts Reaction of Benzene with 2-Phenylbutanedioic Anhydride. Bull. Chem. Soc. Jpn. 1977, 50, 2495-2496.
57. Diago-Meseguer, J.; Palomo-Coll, A. L.; Fernández-Lizarbe, J. R.; Zugaza-Bilbao, A. A new reagent for activating carboxyl groups; preparation and reactions of N,N-bis[2-oxo-3-oxazolidinyl]phosphorodiamidic chloride. Synthesis 1980, 547-551.
58. Waldmann, H. Der Phenylacetyl-(PhAc-)Rest als enzymatisch ablösbare Schutzgruppe für Peptide und Kohlenhydrate: Selektrive Schutzgruppenabspaltungen mit Penicillin-Acylase. Liebigs Ann. Chem. 1998, 1175-1180.
59. Tsunada, T.; Suzuki, M.; Noyori, R. A facile procedure for acetalization under aprotic conditions. Tetrahedron Lett. 1980, 21, 1357-1358.
60. 3Si/TFA reductions were unsuccessful.
61. Attempted ring closure with TFA-acetic anhydride invariably gave the 2-acetylthiophene derivative in quantitative yield.
62. With the exception of 35b, all chiral compounds described in this work are racemic mixtures.
63. Chromatography was performed using a Beckman System Gold HPLC system with a column containing cellulose-based chiral stationary phase (Chiracel, OD 250 × 10 mm), i-PrOH-hexane (20:80) as solvent, and a flow rate of 0.5 mL/min.
64. 2A) = 7.83.
65. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effects of shape on binding of steroids to carrier protein. J. Am. Chem. Soc. 1988, 110, 5959-5967.
66. Cramer, R. D.; De Prierst, S. A.; Patterson, D. E.; Hect, P. The developing practice of Comparative Molecular Field Analysis. In Drug Design: Theory, Methods and Applications; Kubinyi, H., Ed.; Escom: Leiden, 1993; pp 443-485.
67. Thibaut, U. Applications of CoMFA and Related 3D-QSAR Approaches. In Drug Design: Theory, Methods and Applications; Kubinyi, H., Ed.; Escom: Leiden, 1993; pp 661-696.
68. Gaillard, P.; Carrupt, P.-A.; Testa, B.; Boudon, A. Molecular lipophilicity potential, a tool in 3D-QSAR: Method and applications. J. Comput.-Aided Mol. Des. 1994, 8, 83-96.
69. Testa, B.; Carrupt, P.-A.; Gaillard, P.; Tsai, R. S. Intramolecular Interactions Encoded in Lipophilicity. In Lipophilicity in Drug Action and Toxicology; Pliska, V., Testa, B., van der Waterbeemd, H., Eds.; VCH: Weinheim, 1997; pp 49-71.
70. Wold, S.; Johansson, E.; Cocchi, M. PLS - Partial Least Squares Projections to Latent Structures. In Drug Design: Theory, Methods and Applications; Kubinyi, H., Ed.; Escom: Leiden, 1993; pp 523-549.
71. Cramer, R. D., III; Bunce, J. D.; Patterson, D. E. Crossvalidation, bootstrapping and Partial Least Squares compared with Multiple Regression Analysis. Quant. Struct.-Act. Relat. 1988, 7, 18-25.
72. 40
73. 2 for the congeneric (o-methoxyphenyl)-piperazine derivatives If, IIIf, 10f, and 24f.
74. Holtje, H. D.; Folkers, G. In Molecular Modeling, Basic Principles and Applications; Mannhold, R., Kubyi, H., Timmerman, H., Eds.; VCH: Weinheim, 1996; Chapter 3.
75. Stewart, J. J. P. MOPAC: A semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1-103.
76. Carrieri, A.; Brasili, L.; Leonetti, F.; Pigini, M.; Giannella, M.; Bousquet, P.; Carotti, A. 2-D and 3-D Modeling of Imidazoline Receptor liganda: Insights into Pharmacophore. Bioorg. Med. Chem. 1997, 5, 843-856.
77. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990, 112, 6127-6129.
78. Wold, S.; Eriksson, L. Statistical Validation of QSAR Results. In Chemometric Methods in Molecular Design; van de Waterbeemd, H., Ed.; VCH: Weinheim, 1996; pp 309-318.
79. Folkers, G.; Merz, A.; Rognan, D. CoMFA scope and limitations. In Drug Design: Theory, Methods and Applications; Kubinyi, H., Ed.; Escom: Leiden, 1993; pp 583-618.
80. 2A antagonist activity. Quant. Struct.-Act. Relat. 1998, 17, 199-204.
81. Baldwin, J. M. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 1993, 12, 1693-1703.
82. Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatham, T. E.; Ferguson, D. M.; Seibel, G. L.; Singh, C.; Weiner, P. K.; Kollman, P. A. AMBER 4.1; University of California: San Francisco, CA, 1995.
83. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. Procheck: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
84. Hooft, R. W. W.; Vriend, G.; Sander, C.; Abola, E. E. Errors in protein structures. Nature 1996, 381, 272.
85. Fraser, C. M.; Wang, C. D.; Robinson, D. A.; Gocayne, J. D.; Venter, J. C. Site-directed mutagenesis of m1 muscarinic receptors: conserved aspartic acids play important roles in receptor function. Mol. Pharmacol. 1989, 36, 840-847.
86. Strader, C. D.; Sigal, I. S.; Dixon, R. A. F. Structural basis of α-adrenergic receptor function. FASEB J. 1989, 3, 1825-1832.
87. Zhou, W.; Flanagan, C.; Ballesteros, J. A.; Konvicka, K.; Davidson, J. S.; Weinstein, H.; Millar, R. P.; Sealfon, S. C. A. Reciprocal Mutation Supports Helix 2 and Helix 7 Proximity in the Gonadotropin-Releasing Hormone Receptor. Mol. Pharmacol. 1994, 45, 165-170.
88. (82) Molecular Simulations Inc., San Diego, CA.
89. Vogel, A. I. Vogel's Textbook of Practical Organic Chemistry, 5th ed.; Longman: Harlow, U.K., 1989.
90. Sam, J.; Thompson, A. C. Thiaindanones. Thiophene isosters of indanone. J. Pharm. Sci. 1963, 52, 898-901.
91. Nishimura, S.; Nakamura, M.; Suzuki, M.; Imoto, E. Some reactions of 4-oxo-4,5,6,7-tetrahydrothianaphthene. Nippon Kagaku Zasshi 1962, 83, 343-347; Chem. Abstr. 1963, 59, 3862c.
92. Nishimura, S.; Nakamura, M.; Suzuki, M.; Imoto, E. Some reactions of 4-oxo-4,5,6,7-tetrahydrothianaphthene. Nippon Kagaku Zasshi 1962, 83, 343-347; Chem. Abstr. 1963, 59, 3862c.
93. Cagniant, M. P.; Cagniant, P. Contribution a l'etude des hétérocycles soufrés condensés. V. Substitution dans le noyau du tétrahydro-4-5-6-7 thionaphtène au moyen de la réaction de Friedel-Crafts. Bull. Soc. Chim. Fr. 1953, 20, 62-69.
94. Conjat, J. P.; Cagniant, P.; Cagniant, D.; Mirjolet, M. Syntheses dans le domaine des methoxy oxo-4 et oxo-7 tetrahydro-4,5,6,7 benzo[6]thiophenes. Tetrahedron Lett. 1975, 2885-2888.
95. Protais, P.; Costentin, J.; Schwartz, J. C. Climbing behavior induced by apomorphine in mice: A simple test for the study of dopamine receptors in striatum. Psychopharmacology 1976, 50, 1-6.
96. Tallarida, R. J.; Murray, R. B. Manual of Pharmacologic Calculations with Computer Programs, 2nd ed.; Springer-Verlag: New York, 1987; pp 153-158.
97. Bradley, P. B.; Engel, G.; Feniuk, W.; Fozard, J. R.; Humphrey, P. P. A.; Middlemiss, D. N.; Mylecharane, E. J.; Richardson, B. P.; Saxena, P. R. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986, 25, 563-576.
98. Pazos, A.; Cortes, R.; Palacios, J. M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain II. Serotonin-2 receptors. Brain Res. 1985, 346, 231-245.
99. Wong, D. T.; Threlkeld, P. G.; Robertson, D. W. Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology 1991, 5, 43-47.
100. Fukuda, S.; Su, C.; Lee, T. J. F. Mechanisms of extraneuronal serotonin uptake in the rat aorta. J. Pharmacol. Exp. Ther. 1986, 239, 264-269.
101. Gruetter, C. A.; Lemke, S. M.; Anestis, D. K.; Szarek, J. L.; Valentovic, M. A. Potentiation of 5-hydroxytryptamine-induced contraction in rat aorta by chlorpheniramine, citalopram and fluoxetine. Eur. J. Pharmacol. 1992, 217, 109-118.
102. 2 receptors mediating contraction in vascular smooth muscle. J. Pharmacol. Exp. Ther. 1981, 218, 421-425.